RCRA REVISION CHECKLIST 241
Reflects corrections made on March 11, 2019

Management Standards for Hazardous Waste Pharmaceuticals and Amendment to the P075 Listing for Nicotine
                                84 FR 5816-5950
	February 22, 2019
	(RCRA Cluster XXVII, HSWA/Non-HSWA)

Name of State:  Virginia

State Statutory Authority: § 10.1-1402 of the Code of Virginia

Title of Regulations:  	Virginia Hazardous Waste Management Regulations, 9VAC20-60

Effective Date:   August 23, 2019 (VA.R. Volume 35, Issue 24, July 22, 2019)

Date Checklist Completed: August 26, 2019

                             FEDERAL REQUIREMENTS

                             FEDERAL RCRA CITATION

                           ANALOGOUS STATE CITATION

                               STATE ANALOG IS:

                                  EQUIV-ALENT

                                     LESS
                                    STRIN-
                                     GENT

                                MORE STRIN-GENT

                               BROADER IN SCOPE

            PART 261 IDENTIFICATION AND LISTING OF HAZARDOUS WASTE

                               SUBPART A GENERAL

Revise to read: Any mixture of domestic sewage and other wastes that passes through a sewer system to a publicly-owned treatment works for treatment, except as prohibited by § 266.505 and Clean Water Act requirements at 40 CFR 403.5(b). "Domestic sewage" means untreated sanitary wastes that pass through a sewer system.
261.4(a)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-261A.
                                       X
                                     Yes.

Containers of hazardous waste pharmaceuticals are subject to § 266.507 for determining when they are considered empty, in lieu of this section, except as provided by § 266.507(c) and (d).
261.7(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-261A.
                                       X

                      SUBPART D LISTS OF HAZARDOUS WASTES

Revise to read: Any residue remaining in a container or in an inner liner removed from a container that has held any commercial chemical product or manufacturing chemical intermediate having the generic name listed in paragraphs (e) or (f) of this section, unless the container is empty as defined in § 261.7(b) or § 266.507 of this chapter.
261.33(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-261A.
                                       X

[Comment: Unless the residue is being beneficially used or reused, or legitimately recycled or reclaimed; or being accumulated, stored, transported or treated prior to such use, re-use, recycling or reclamation, EPA considers the residue to be intended for discard, and thus, a hazardous waste. An example of a legitimate re-use of the residue would be where the residue remains in the container and the container is used to hold the same commercial chemical product or manufacturing chemical intermediate it previously held. An example of the discard of the residue would be where the drum is sent to a drum reconditioner who reconditions the drum but discards the residue.]
261.33(c) Comment
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-261A.
                                       X

                                                                              1
Revise the entries for P075 in the Table below:
261.33(e) Table
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-261A.
                                       X

Hazardous waste No.
Chemical abstracts No.
Substance

P075
[1]54−11−5
Nicotine, & salts (this listing does not include patches, gums and lozenges that are FDA-approved over-the-counter nicotine replacement therapies)

P075
[1]54-11-5
Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-, & salts (this listing does not include patches, gums and lozenges that are FDA-approved over-the-counter nicotine replacement therapies)

P075
[1]54−11−5
Nicotine, & salts (this listing does not include patches, gums and lozenges that are FDA-approved over-the-counter nicotine replacement therapies)

P075
[1]54−11−5
Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-, & salts (this listing does not include patches, gums and lozenges that are FDA-approved over-the-counter nicotine replacement therapies)

[1]CAS Number given for parent compound only.

      PART 262  -  STANDARDS APPLICABLE TO GENERATORS OF HAZARDOUS WASTE

                               SUBPART A GENERAL

All reverse distributors (as defined in § 266.500) are subject to 40 CFR part 266 subpart P for the management of hazardous waste pharmaceuticals in lieu of this part.
262.10(m)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-262A.
                                       X

Each healthcare facility (as defined in § 266.500) must determine whether it is subject to 40 CFR part 266 subpart P for the management of hazardous waste pharmaceuticals, based on the total hazardous waste it generates per calendar month (including both hazardous waste pharmaceuticals and non-pharmaceutical hazardous waste). A healthcare facility that generates more than 100 kg (220 pounds) of hazardous waste per calendar month, or more than 1 kg (2.2 pounds) of acute hazardous waste per calendar month, or more than 100 kg (220 pounds) per calendar month of any residue or contaminated soil, water, or other debris, resulting from the clean-up of a spill, into or on any land or water, of any acute hazardous wastes listed in § 261.31 or § 261.33(e), is subject to 40 CFR part 266 subpart P for the management of hazardous waste pharmaceuticals in lieu of this part. A healthcare facility that is a very small quantity generator when counting all of its hazardous waste, including both its hazardous waste pharmaceuticals and its non-pharmaceutical hazardous waste, remains subject to § 262.14 and is not subject to part 266 subpart P, except for §§ 266.505 and 266.507 and the optional provisions of § 266.504.
262.10(n)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-262A.
                                       X

Is a hazardous waste pharmaceutical, as defined in § 266.500, that is subject to or managed in accordance with 40 CFR part 266 subpart P or is a hazardous waste pharmaceutical that is also a Drug Enforcement Administration controlled substance and is conditionally exempt under § 266.506.
262.13(c)(9)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-262A.
                                       X

A reverse distributor (as defined in § 266.500), if the hazardous waste pharmaceutical is a potentially creditable hazardous waste pharmaceutical generated by a healthcare facility (as defined in § 266.500).
262.14(a)(5)(ix)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-262A.
                                       X

A healthcare facility (as defined in § 266.500) that meets the conditions in §§ 266.502(l) and 266.503(b), as applicable, to accept non-creditable hazardous waste pharmaceuticals and potentially creditable hazardous waste pharmaceuticals from an off-site healthcare facility that is a very small quantity generator.
262.14(a)(5)(x)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-262A.
                                       X

PART 264 -- STANDARDS FOR OWNERS AND OPERATORS OF HAZARDOUS WASTE TREATMENT, STORAGE, AND DISPOSAL FACILITIES

                               SUBPART A GENERAL

Reverse distributors accumulating potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals, as defined in § 266.500. Reverse distributors are subject to regulation under 40 CFR part 266 subpart P in lieu of this part for the accumulation of potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals.
264.1(g)(13)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-264A.
                                       X

PART 265 -- INTERIM STATUS STANDARDS FOR OWNERS AND OPERATORS OF HAZARDOUS WASTE TREATMENT, STORAGE, AND DISPOSAL FACILITIES

                               SUBPART A GENERAL

Reverse distributors accumulating potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals, as defined in § 266.500. Reverse distributors are subject to regulation under 40 CFR part 266 subpart P in lieu of this part for the accumulation of potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals.
265.1(c)(16)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-265A.
                                       X

PART 266 -- STANDARDS FOR THE MANAGEMENT OF SPECIFIC HAZARDOUS WASTES AND SPECIFIC TYPES OF HAZARDOUS WASTE MANAGEMENT FACILITIES

                  SUBPART P -- HAZARDOUS WASTE PHARMACEUTICALS

Add heading: Definitions for this subpart.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The following definitions apply to this subpart:
266.500 introduction
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Evaluated hazardous waste pharmaceutical means a prescription hazardous waste pharmaceutical that has been evaluated by a reverse distributor in accordance with § 266.510(a)(3) and will not be sent to another reverse distributor for further evaluation or verification of manufacture credit.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Hazardous waste pharmaceutical means a pharmaceutical that is a solid waste, as defined in § 261.2, and exhibits one or more characteristics identified in part 261 subpart C or is listed in part 261 subpart D. A pharmaceutical is not a solid waste, as defined in § 261.2, and therefore not a hazardous waste pharmaceutical, if it is legitimately used/reused (e.g., lawfully donated for its intended purpose) or reclaimed. An over-the-counter pharmaceutical, dietary supplement, or homeopathic drug is not a solid waste, as defined in § 261.2, and therefore not a hazardous waste pharmaceutical, if it has a reasonable expectation of being legitimately used/reused (e.g., lawfully redistributed for its intended purpose) or reclaimed.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Healthcare facility means any person that is lawfully authorized to (1) Provide preventative, diagnostic, therapeutic, rehabilitative, maintenance or palliative care, and counseling, service, assessment or procedure with respect to the physical or mental condition, or functional status, of a human or animal or that affects the structure or function of the human or animal body; or
(2) Distribute, sell, or dispense pharmaceuticals, including over-the-counter pharmaceuticals, dietary supplements, homeopathic drugs, or prescription pharmaceuticals. This definition includes, but is not limited to, wholesale distributors, third-party logistics providers that serve as forward distributors, military medical logistics facilities, hospitals, psychiatric hospitals, ambulatory surgical centers, health clinics, physicians' offices, optical and dental providers, chiropractors, long-term care facilities, ambulance services, pharmacies, long-term care pharmacies, mail-order pharmacies, retailers of pharmaceuticals, veterinary clinics, and veterinary hospitals. This definition does not include pharmaceutical manufacturers, reverse distributors, or reverse logistics centers.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Household waste pharmaceutical means a pharmaceutical that is a solid waste, as defined in § 261.2, but is excluded from being a hazardous waste under § 261.4(b)(1).
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Long-term care facility means a licensed entity that provides assistance with activities of daily living, including managing and administering pharmaceuticals to one or more individuals at the facility. This definition includes, but is not limited to, hospice facilities, nursing facilities, skilled nursing facilities, and the nursing and skilled nursing care portions of continuing care retirement communities. Not included within the scope of this definition are group homes, independent living communities, assisted living facilities, and the independent and assisted living portions of continuing care retirement communities.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Non-creditable hazardous waste pharmaceutical means a prescription hazardous waste pharmaceutical that does not have a reasonable expectation to be eligible for manufacturer credit or a nonprescription hazardous waste pharmaceutical that does not have a reasonable expectation to be legitimately used/reused or reclaimed. This includes but is not limited to, investigational drugs, free samples of pharmaceuticals received by healthcare facilities, residues of pharmaceuticals remaining in empty containers, contaminated personal protective equipment, floor sweepings, and clean-up material from the spills of pharmaceuticals.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Non-hazardous waste pharmaceutical means a pharmaceutical that is a solid waste, as defined in § 261.2, and is not listed in 40 CFR part 261 subpart D, and does not exhibit a characteristic identified in 40 CFR part 261 subpart C.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Non-pharmaceutical hazardous waste means a solid waste, as defined in § 261.2, that is listed in 40 CFR part 261 subpart D, or exhibits one or more characteristics identified in 40 CFR part 261 subpart C, but is not a pharmaceutical, as defined in this section.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Pharmaceutical means any drug or dietary supplement for use by humans or other animals; any electronic nicotine delivery system (e.g., electronic cigarette or vaping pen); or any liquid nicotine (e-liquid) packaged for retail sale for use in electronic nicotine delivery systems (e.g., pre-filled cartridges or vials). This definition includes, but is not limited to, dietary supplements, as defined by the Federal Food, Drug and Cosmetic Act; prescription drugs, as defined by 21 CFR 203.3(y); over-the-counter drugs; homeopathic drugs; compounded drugs; investigational new drugs; pharmaceuticals remaining in non-empty containers; personal protective equipment contaminated with pharmaceuticals; and clean-up material from spills of pharmaceuticals. This definition does not include dental amalgam or sharps.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Potentially creditable hazardous waste pharmaceutical means a prescription hazardous waste pharmaceutical that has a reasonable expectation to receive manufacturer credit and is
(1) In original manufacturer packaging (except pharmaceuticals that were subject to a recall);
(2) Undispensed; and
(3) Unexpired or less than one year past expiration date. The term does not include evaluated hazardous waste pharmaceuticals or nonprescription pharmaceuticals including, but not limited to, over-the-counter drugs, homeopathic drugs, and dietary supplements.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Reverse distributor means any person that receives and accumulates prescription pharmaceuticals that are potentially creditable hazardous waste pharmaceuticals for the purpose of facilitating or verifying manufacturer credit. Any person, including forward distributors, third-party logistics providers, and pharmaceutical manufacturers, that processes prescription pharmaceuticals for the facilitation or verification of manufacturer credit is considered a reverse distributor.
266.500
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Add heading: Applicability.
266.501
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that is a very small quantity generator when counting all of its hazardous waste, including both its hazardous waste pharmaceuticals and its non-pharmaceutical hazardous waste, remains subject to § 262.14 and is not subject to this subpart, except for §§ 266.505 and 266.507 and the optional provisions of § 266.504.
266.501(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that is a very small quantity generator when counting all of its hazardous waste, including both its hazardous waste pharmaceuticals and its non-pharmaceutical hazardous waste, has the option of complying with § 266.501(d) for the management of its hazardous waste pharmaceuticals as an alternative to complying with § 262.14 and the optional provisions of § 266.504.
266.501(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility or reverse distributor remains subject to all applicable hazardous waste regulations with respect to the management of its non-pharmaceutical hazardous waste.
266.501(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

With the exception of healthcare facilities identified in paragraph (a) of this section, a healthcare facility is subject to the following in lieu of parts 262 through265:
266.501(d)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Sections 266.502 and 266.505 through 266.508 of this subpart with respect to the management of:
266.501(d)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Non-creditable hazardous waste pharmaceuticals, and
266.501(d)(1)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Potentially creditable hazardous waste pharmaceuticals if they are not destined for a reverse distributor.
266.501(d)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Sections 262.502(a), 266.503, 266.505 through 266.507 and 266.509 of this subpart with respect to the management of potentially creditable hazardous waste pharmaceuticals that are prescription pharmaceuticals and are destined for a reverse distributor.
266.501(d)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A reverse distributor is subject to §§ 266.505 through 266.510 of this subpart in lieu of parts 262 through 265 with respect to the management of hazardous waste pharmaceuticals.
266.501(e)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Hazardous waste pharmaceuticals generated or managed by entities other than healthcare facilities and reverse distributors (e.g., pharmaceutical manufacturers and reverse logistics centers) are not subject to this subpart. Other generators are subject to 40 CFR part 262 for the generation and accumulation of hazardous wastes, including hazardous waste pharmaceuticals.
266.501(f)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The following are not subject to 40 CFR parts 260 through 273, except as specified:
266.501(g)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Pharmaceuticals that are not solid waste, as defined by § 261.2, because they are legitimately used/reused (e.g., lawfully donated for their intended purpose) or reclaimed.
266.501(g)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Over-the-counter pharmaceuticals, dietary supplements, or homeopathic drugs that are not solid wastes, as defined by § 261.2, because they have a reasonable expectation of being legitimately used/reused (e.g., lawfully redistributed for their intended purpose) or reclaimed.
266.501(g)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Pharmaceuticals being managed in accordance with a recall strategy that has been approved by the Food and Drug Administration in accordance with 21 CFR part 7 subpart C. This subpart does apply to the management of the recalled hazardous waste pharmaceuticals after the Food and Drug Administration approves the destruction of the recalled items.
266.501(g)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Pharmaceuticals being managed in accordance with a recall corrective action plan that has been accepted by the Consumer Product Safety Commission in accordance with 16 CFR part 1115.  This subpart does apply to the management of the recalled hazardous waste pharmaceuticals after the Consumer Product Safety Commission approves the destruction of the recalled items.
266.501(g)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Pharmaceuticals stored according to a preservation order, or during an investigation or judicial proceeding until after the preservation order, investigation, or judicial proceeding has concluded and/or a decision is made to discard the pharmaceuticals.
266.501(g)(5)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Investigational new drugs for which an investigational new drug application is in effect in accordance with the Food and Drug Administration's regulations in 21 CFR part 312. This subpart does apply to the management of the investigational new drug after the decision is made to discard the investigational new drug or the Food and Drug Administration approves the destruction of the investigational new drug, if the investigational new drug is a hazardous waste.
266.501(g)(6)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Household waste pharmaceuticals, including those that have been collected by an authorized collector (as defined by the Drug Enforcement Administration), provided the authorized collector complies with the conditional exemption in §§ 266.506(a)(2) and 266.506(b).
266.501(g)(7)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Add heading: Standards for healthcare facilities managing non-creditable hazardous waste pharmaceuticals.
266.502
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Notification and withdrawal from this subpart for healthcare facilities managing hazardous waste pharmaceuticals
266.502(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Notification. A healthcare facility must notify the EPA Regional Administrator, using the Site Identification Form (EPA Form 8700-12), that it is a healthcare facility operating under this subpart. A healthcare facility is not required to fill out Box 10.B. (Waste Codes for Federally Regulated Hazardous Waste) of the Site Identification Form with respect to its hazardous waste pharmaceuticals. A healthcare facility must submit a separate notification (Site Identification Form) for each site or EPA identification number.
266.502(a)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that already has an EPA identification number must notify the EPA Regional Administrator, using the Site Identification Form (EPA Form 8700-12), that it is a healthcare facility as part of its next Biennial Report, if it is required to submit one; or if not required to submit a Biennial Report, within 60 days of the effective date of this subpart, or within 60 days of becoming subject to this subpart.
266.502(a)(1)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that does not have an EPA identification number must obtain one by notifying the EPA Regional Administrator, using the Site Identification Form (EPA Form 8700-12), that it is a healthcare facility as part of its next Biennial Report, if it is required to submit one; or if not required to submit a Biennial Report, within 60 days of the effective date of this subpart, or within 60 days of becoming subject to this subpart.
266.502(a)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must keep a copy of its notification on file for as long as the healthcare facility is subject to this subpart.
266.502(a)(1)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Withdrawal. A healthcare facility that operated under this subpart but is no longer subject to this subpart, because it is a very small quantity generator under § 262.14, and elects to withdraw from this subpart, must notify the appropriate EPA Regional Administrator using the Site Identification Form (EPA Form 8700-12) that it is no longer operating under this subpart. A healthcare facility is not required to fill out Box 10.B. (Waste Codes for Federally Regulated Hazardous Waste) of the Site Identification Form with respect to its hazardous waste pharmaceuticals. A healthcare facility must submit a separate notification (Site Identification Form) for each EPA identification number.
266.502(a)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must submit the Site Identification Form notifying that it is withdrawing from this subpart before it begins operating under the conditional exemption of § 262.14.
266.502(a)(2)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must keep a copy of its withdrawal on file for three years from the date of signature on the notification of its withdrawal.
266.502(a)(2)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Training of personnel managing non-creditable hazardous waste pharmaceuticals at healthcare facilities. A healthcare facility must ensure that all personnel that manage non-creditable hazardous waste pharmaceuticals are thoroughly familiar with proper waste handling and emergency procedures relevant to their responsibilities during normal facility operations and emergencies.
266.502(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Hazardous waste determination for non-creditable pharmaceuticals. A healthcare facility that generates a solid waste that is a non-creditable pharmaceutical must determine whether that pharmaceutical is a hazardous waste pharmaceutical (i.e., it exhibits a characteristic identified in 40 CFR part 261 subpart C or is listed in 40 CFR part 261 subpart D) in order to determine whether the waste is subject to this subpart. A healthcare facility may choose to manage its non-hazardous waste pharmaceuticals as non-creditable hazardous waste pharmaceuticals under this subpart.
266.502(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Standards for containers used to accumulate non-creditable hazardous waste pharmaceuticals at healthcare facilities.
266.502(d)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must place non-creditable hazardous waste pharmaceuticals in a container that is structurally sound, compatible with its contents, and that lacks evidence of leakage, spillage, or damage that could cause leakage under reasonably foreseeable conditions.
266.502(d)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that manages ignitable or reactive non-creditable hazardous waste pharmaceuticals, or that mixes or commingles incompatible non-creditable hazardous waste pharmaceuticals must manage the container so that it does not have the potential to:
266.502(d)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Generate extreme heat or pressure, fire or explosion, or violent reaction;
266.502(d)(2)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Produce uncontrolled toxic mists, fumes, dusts, or gases in sufficient quantities to threaten human health;
266.502(d)(2)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Produce uncontrolled flammable fumes or gases in sufficient quantities to pose a risk of fire or explosions;
266.502(d)(2)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Damage the structural integrity of the container of non-creditable hazardous waste pharmaceuticals; or
266.502(d)(2)(iv)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Through other like means threaten human health or the environment.
266.502(d)(2)(v)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must keep containers of non-creditable hazardous waste pharmaceuticals closed and secured in a manner that prevents unauthorized access to its contents.
266.502(d)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility may accumulate non-creditable hazardous waste pharmaceuticals and non-hazardous non-creditable waste pharmaceuticals in the same container, except that non-creditable hazardous waste pharmaceuticals prohibited from being combusted because of the dilution prohibition of § 268.3(c) must be accumulated in separate containers and labeled with all applicable hazardous waste numbers (i.e., hazardous waste codes).
266.502(d)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Labeling containers used to accumulate non-creditable hazardous waste pharmaceuticals at healthcare facilities. A healthcare facility must label or clearly mark each container of non-creditable hazardous waste pharmaceuticals with the phrase "Hazardous Waste Pharmaceuticals."
266.502(e)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Maximum accumulation time for non-creditable hazardous waste pharmaceuticals at healthcare facilities.
266.502(f)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility may accumulate non-creditable hazardous waste pharmaceuticals on site for one year or less without a permit or having interim status.
266.502(f)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that accumulates non-creditable hazardous waste pharmaceuticals on-site must demonstrate the length of time that the non-creditable hazardous waste pharmaceuticals have been accumulating, starting from the date it first becomes a waste. A healthcare facility may make this demonstration by any of the following methods:
266.502(f)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Marking or labeling the container of non-creditable hazardous waste pharmaceuticals with the date that the non-creditable hazardous waste pharmaceuticals became a waste;
266.502(f)(2)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Maintaining an inventory system that identifies the date the non-creditable hazardous waste pharmaceuticals being accumulated first became a waste;
266.502(f)(2)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Placing the non-creditable hazardous waste pharmaceuticals in a specific area and identifying the earliest date that any of the non-creditable hazardous waste pharmaceuticals in the area became a waste.
266.502(f)(2)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Land disposal restrictions for non-creditable hazardous waste pharmaceuticals. The non-creditable hazardous waste pharmaceuticals generated by a healthcare facility are subject to the land disposal restrictions of 40 CFR part 268. A healthcare facility that generates non-creditable hazardous waste pharmaceuticals must comply with the land disposal restrictions in accordance with § 268.7(a) requirements, except that it is not required to identify the hazardous waste numbers (i.e., hazardous waste codes) on the land disposal restrictions notification.
266.502(g)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Procedures for healthcare facilities for managing rejected shipments of non-creditable hazardous waste pharmaceuticals. A healthcare facility that sends a shipment of non-creditable hazardous waste pharmaceuticals to a designated facility with the understanding that the designated facility can accept and manage the waste, and later receives that shipment back as a rejected load in accordance with the manifest discrepancy provisions of § 264.72 or § 265.72 of this chapter may accumulate the returned non-creditable hazardous waste pharmaceuticals on site for up to an additional 90 days provided the rejected or returned shipment is managed in accordance with paragraphs (d) and (e) of this section. Upon receipt of the returned shipment, the healthcare facility must:
266.502(h)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Sign either:
266.502(h)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Item 18c of the original manifest, if the original manifest was used for the returned shipment; or
266.502(h)(1)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Item 20 of the new manifest, if a new manifest was used for the returned shipment;
266.502(h)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Provide the transporter a copy of the manifest;
266.502(h)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Within 30 days of receipt of the rejected shipment, send a copy of the manifest to the designated facility that returned the shipment to the healthcare facility; and
266.502(h)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Within 90 days of receipt of the rejected shipment, transport or offer for transport the returned shipment in accordance with the shipping standards of § 266.508(a).
266.502(h)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Reporting by healthcare facilities for non-creditable hazardous waste pharmaceuticals
266.502(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Biennial reporting by healthcare facilities. Healthcare facilities are not subject to biennial reporting requirements under § 262.41, with respect to non-creditable hazardous waste pharmaceuticals managed under this subpart.
266.502(i)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Exception reporting by healthcare facilities for a missing copy of the manifest.
266.502(i)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

For shipments from a healthcare facility to a designated facility:
266.502(i)(2)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

If a healthcare facility does not receive a copy of the manifest with the signature of the owner or operator of the designated facility within 60 days of the date the non-creditable hazardous waste pharmaceuticals were accepted by the initial transporter, the healthcare facility must submit:
266.502(i)(2)(i)(A)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A legible copy of the original manifest, indicating that the healthcare facility has not received confirmation of delivery, to the EPA Regional Administrator for the Region in which the healthcare facility is located; and
266.502(i)(2)(i)(A)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A handwritten or typed note on the manifest itself, or on an attached sheet of paper, stating that the return copy was not received and explaining the efforts taken to locate the non-creditable hazardous waste pharmaceuticals and the results of those efforts.
266.502(i)(2)(i)(A)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Reserved
266.502(i)(2)(i)(B)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

For shipments rejected by the designated facility and shipped to an alternate facility.
266.502(i)(2)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

If a healthcare facility does not receive a copy of the manifest for a rejected shipment of the non-creditable hazardous waste pharmaceuticals that is forwarded by the designated facility to an alternate facility (using appropriate manifest procedures), with the signature of the owner or operator of the alternate facility, within 60 days of the date the non-creditable hazardous waste was accepted by the initial transporter forwarding the shipment of non-creditable hazardous waste pharmaceuticals from the designated facility to the alternate facility, the healthcare facility must submit:
266.502(i)(2)(ii)(A)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A legible copy of the original manifest, indicating that the healthcare facility has not received confirmation of delivery, to the EPA Regional Administrator for the Region in which the healthcare facility is located; and
266.502(i)(2)(ii)(A)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A handwritten or typed note on the manifest itself, or on an attached sheet of paper, stating that the return copy was not received and explaining the efforts taken to locate the non-creditable hazardous waste pharmaceuticals and the results of those efforts.
266.502(i)(2)(ii)(A)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Reserved
266.502(i)(2)(ii)(B)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Additional reports. The EPA Regional Administrator may require healthcare facilities to furnish additional reports concerning the quantities and disposition of non-creditable hazardous waste pharmaceuticals.
266.502(i)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Recordkeeping by healthcare facilities for non-creditable hazardous waste pharmaceuticals.
266.502(j)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must keep a copy of each manifest signed in accordance with § 262.23(a) for three years or until it receives a signed copy from the designated facility which received the non-creditable hazardous waste pharmaceuticals. This signed copy must be retained as a record for at least three years from the date the waste was accepted by the initial transporter.
266.502(j)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must keep a copy of each exception report for a period of at least three years from the date of the report.
266.502(j)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility must keep records of any test results, waste analyses, or other determinations made to support its hazardous waste determination(s) consistent with § 262.11(f), for at least three years from the date the waste was last sent to on-site or off-site treatment, storage or disposal. A healthcare facility that manages all of its non-creditable non-hazardous waste pharmaceuticals as non-creditable hazardous waste pharmaceuticals is not required to keep documentation of hazardous waste determinations.
266.502(j)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The periods of retention referred to in this section are extended automatically during the course of any unresolved enforcement action regarding the regulated activity, or as requested by the EPA Regional Administrator.
266.502(j)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

All records must be readily available upon request by an inspector.
266.502(j)(5)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Response to spills of non-creditable hazardous waste pharmaceuticals at healthcare facilities.  A healthcare facility must immediately contain all spills of non-creditable hazardous waste pharmaceuticals and manage the spill clean-up materials as non-creditable hazardous waste pharmaceuticals in accordance with the requirements of this subpart.
266.502(k)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Accepting non-creditable hazardous waste pharmaceuticals from an off-site healthcare facility that is a very small quantity generator. A healthcare facility may accept non-creditable hazardous waste pharmaceuticals from an off-site healthcare facility that is a very small quantity generator under § 262.14, without a permit or without having interim status, provided the receiving healthcare facility:
266.502(l)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Is under the control of the same person (as defined in § 260.10) as the very small quantity generator healthcare facility that is sending the non-creditable hazardous waste pharmaceuticals off-site ("control," for the purposes of this section, means the power to direct the policies of the healthcare facility, whether by the ownership of stock, voting rights, or otherwise, except that contractors who operate healthcare facilities on behalf of a different person as defined in § 260.10 of this chapter shall not be deemed to "control" such healthcare facilities) or has a contractual or other documented business relationship whereby the receiving healthcare facility supplies pharmaceuticals to the very small quantity generator healthcare facility;
266.502(l)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Is operating under this subpart for the management of its non-creditable hazardous waste pharmaceuticals;
266.502(l)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Manages the non-creditable hazardous waste pharmaceuticals that it receives from off site in compliance with this subpart; and
266.502(l)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Keeps records of the non-creditable hazardous waste pharmaceuticals shipments it receives from off site for three years from the date that the shipment is received.
266.502(l)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Add heading: Standards for healthcare facilities managing potentially creditable hazardous waste pharmaceuticals.
266.503
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Hazardous waste determination for potentially creditable pharmaceuticals. A healthcare facility that generates a solid waste that is a potentially creditable pharmaceutical must determine whether the potentially creditable pharmaceutical is a potentially creditable hazardous waste pharmaceutical (i.e., it is listed in 40 CFR part 261 subpart D or exhibits a characteristic identified in 40 CFR part 261 subpart C). A healthcare facility may choose to manage its potentially creditable non-hazardous waste pharmaceuticals as potentially creditable hazardous waste pharmaceuticals under this subpart.
266.503(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Accepting potentially creditable hazardous waste pharmaceuticals from an off-site healthcare facility that is a very small quantity generator. A healthcare facility may accept potentially creditable hazardous waste pharmaceuticals from an off-site healthcare facility that is a very small quantity generator under § 262.14, without a permit or without having interim status, provided the receiving healthcare facility:
266.503(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Is under the control of the same person, as defined in § 260.10, as the very small quantity generator healthcare facility that is sending the potentially creditable hazardous waste pharmaceuticals off site, or has a contractual or other documented business relationship whereby the receiving healthcare facility supplies pharmaceuticals to the very small quantity generator healthcare facility;
266.503(b)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Is operating under this subpart for the management of its potentially creditable hazardous waste pharmaceuticals;
266.503(b)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Manages the potentially creditable hazardous waste pharmaceuticals that it receives from off site in compliance with this subpart; and
266.503(b)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Keeps records of the potentially creditable hazardous waste pharmaceuticals shipments it receives from off site for three years from the date that the shipment is received.
266.503(b)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Prohibition. Healthcare facilities are prohibited from sending hazardous wastes other than potentially creditable hazardous waste pharmaceuticals to a reverse distributor.
266.503(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Biennial Reporting by healthcare facilities. Healthcare facilities are not subject to biennial reporting requirements under § 262.41 with respect to potentially creditable hazardous waste pharmaceuticals managed under this subpart.
266.503(d)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Recordkeeping by healthcare facilities.
266.503(e)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A healthcare facility that initiates a shipment of potentially creditable hazardous waste pharmaceuticals to a reverse distributor must keep the following records (paper or electronic) for each shipment of potentially creditable hazardous waste pharmaceuticals for three years from the date of shipment:
266.503(e)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The confirmation of delivery; and
266.503(e)(1)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The shipping papers prepared in accordance with 49 CFR part 172 subpart C, if applicable.
266.503(e)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B. 4.
                                       X

The periods of retention referred to in this section are extended automatically during the course of any unresolved enforcement action regarding the regulated activity, or as requested by the EPA Regional Administrator.
266.503(e)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

All records must be readily available upon request by an inspector.
266.503(e)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Response to spills of potentially creditable hazardous waste pharmaceuticals at healthcare facilities. A healthcare facility must immediately contain all spills of potentially creditable hazardous waste pharmaceuticals and manage the spill clean-up materials as non-creditable hazardous waste pharmaceuticals in accordance with this subpart.
266.503(f)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Add heading: Healthcare facilities that are very small quantity generators for both hazardous waste pharmaceuticals and non-pharmaceutical hazardous waste.
266.504
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Potentially creditable hazardous waste pharmaceuticals. A healthcare facility that is a very small quantity generator for both hazardous waste pharmaceuticals and non-pharmaceutical hazardous waste may send its potentially creditable hazardous waste pharmaceuticals to a reverse distributor.
266.504(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Off-site collection of hazardous waste pharmaceuticals generated by a healthcare facility that is a very small quantity generator. A healthcare facility that is a very small quantity generator for both hazardous waste pharmaceuticals and non-pharmaceutical hazardous waste may send its hazardous waste pharmaceuticals off-site to another healthcare facility, provided:
266.504(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The receiving healthcare facility meets the conditions in § 266.502(l) of this subpart and § 266.503(b), as applicable, or
266.504(b)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The very small quantity generator healthcare facility meets the conditions in § 262.14(a)(5)(viii) and the receiving large quantity generator meets the conditions in § 262.17(f).
266.504(b)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Long-term care facilities that are very small quantity generators. A long-term care facility that is a very small quantity generator for both hazardous waste pharmaceuticals and non-pharmaceutical hazardous waste may dispose of its hazardous waste pharmaceuticals (excluding contaminated personal protective equipment or clean-up materials) in an on-site collection receptacle of an authorized collector (as defined by the Drug Enforcement Administration) that is registered with the Drug Enforcement Administration provided the contents are collected, stored, transported, destroyed and disposed of in compliance with all applicable Drug Enforcement Administration regulations for controlled substances.
266.504(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Long-term care facilities with 20 beds or fewer. A long-term care facility with 20 beds or fewer is presumed to be a very small quantity generator subject to § 262.14 for both hazardous waste pharmaceuticals and non-pharmaceutical hazardous waste and not subject to this subpart, except for §§ 266.505 and 266.507 and the other optional provisions of this section. The EPA Regional Administrator has the responsibility to demonstrate that a long-term care facility with 20 beds or fewer generates quantities of hazardous waste that are in excess of the very small quantity generator limits as defined in § 260.10. A long-term care facility with more than 20 beds that operates as a very small quantity generator under § 262.14 must demonstrate that it generates quantities of hazardous waste that are within the very small quantity generator limits as defined by § 260.10.
266.504(d)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

                                                                           2, H
Add heading: Prohibition of sewering hazardous waste pharmaceuticals.
266.505
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

                                                                              H
All healthcare facilities -- including very small quantity generators operating under § 262.14 in lieu of this subpart -- and reverse distributors are prohibited from discharging hazardous waste pharmaceuticals to a sewer system that passes through to a publicly-owned treatment works. Healthcare facilities and reverse distributors remain subject to the prohibitions in 40 CFR 403.5(b)(1).
266.505
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Add heading: Conditional exemptions for hazardous waste pharmaceuticals that are also controlled substances and household waste pharmaceuticals collected in a take-back event or program.
266.506
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Conditional exemptions. Provided the conditions of paragraph (b) of this section are met, the following are exempt from 40 CFR parts 262 through 273:
266.506(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Hazardous waste pharmaceuticals that are also listed on a schedule of controlled substances by the Drug Enforcement Administration in 21 CFR part 1308, and
266.506(a)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Household waste pharmaceuticals that are collected in a take-back event or program, including those that are collected by an authorized collector (as defined by the Drug Enforcement Administration) registered with the Drug Enforcement Administration that commingles the household waste pharmaceuticals with controlled substances from an ultimate user (as defined by the Drug Enforcement Administration).
266.506(a)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Conditions for exemption. The hazardous waste pharmaceuticals must be:
266.506(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Managed in compliance with the sewer prohibition of § 266.505 and
266.506(b)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Collected, stored, transported, and disposed of in compliance with all applicable Drug Enforcement Administration regulations for controlled substances; and
266.506(b)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Destroyed by a method that Drug Enforcement Administration has publicly deemed in writing to meet their non-retrievable standard of destruction or combusted at one of the following:
266.506(b)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

A permitted large municipal waste combustor, subject to 40 CFR part 62 subpart FFF or applicable state plan for existing large municipal waste combustors, or 40 CFR part 60 subparts Eb for new large municipal waste combustors; or
266.506(b)(3)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B.5
                                       X

A permitted small municipal waste combustor, subject to 40 CFR part 62 subpart JJJ or applicable state plan for existing small municipal waste combustors, or 40 CFR part 60 subparts AAAA for new small municipal waste combustors; or
266.506(b)(3)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B.6
                                       X

A permitted hospital, medical and infectious waste incinerator, subject to 40 CFR part 62 subpart HHH or applicable state plan for existing hospital, medical and infectious waste incinerators, or 40 CFR part 60 subpart Ec for new hospital, medical and infectious waste incinerators.
266.506(b)(3)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B.7
                                       X

A permitted commercial and industrial solid waste incinerator, subject to 40 CFR part 62 subpart III or applicable state plan for existing commercial and industrial solid waste incinerators, or 40 CFR part 60 subpart CCCC for new commercial and industrial solid waste incinerators.
266.506(b)(3)(iv)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B.8
                                       X

A permitted hazardous waste combustor subject to 40 CFR part 63 subpart EEE.
266.506(b)(3)(v)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B.9
                                       X

Add heading: Residues of hazardous waste pharmaceuticals in empty containers.
266.507
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Stock, dispensing and unit-dose containers. A stock bottle, dispensing bottle, vial, or ampule (not to exceed 1 liter or 10,000 pills); or a unit-dose container (e.g., a unit-dose packet, cup, wrapper, blister pack, or delivery device) is considered empty and the residues are not regulated as hazardous waste provided the pharmaceuticals have been removed from the stock bottle, dispensing bottle, vial, ampule, or the unit-dose container using the practices commonly employed to remove materials from that type of container.
266.507(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Syringes. A syringe is considered empty and the residues are not regulated as hazardous waste under this subpart provided the contents have been removed by fully depressing the plunger of the syringe. If a syringe is not empty, the syringe must be placed with its remaining hazardous waste pharmaceuticals into a container that is managed and disposed of as a non-creditable hazardous waste pharmaceutical under this subpart and any applicable federal, state, and local requirements for sharps containers and medical waste.
266.507(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Intravenous (IV) bags. An IV bag is considered empty and the residues are not regulated as hazardous waste provided the pharmaceuticals in the IV bag have been fully administered to a patient. If an IV bag is not empty, the IV bag must be placed with its remaining hazardous waste pharmaceuticals into a container that is managed and disposed of as a non-creditable hazardous waste pharmaceutical under this subpart, unless the IV bag held non-acute hazardous waste pharmaceuticals and is empty as defined in § 261.7(b)(1).
266.507(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Other containers, including delivery devices. Hazardous waste pharmaceuticals remaining in all other types of unused, partially administered, or fully administered containers must be managed as non-creditable hazardous waste pharmaceuticals under this subpart, unless the container held non-acute hazardous waste pharmaceuticals and is empty as defined in § 261.7(b)(1) or (2). This includes, but is not limited to, residues in inhalers, aerosol cans, nebulizers, tubes of ointments, gels, or creams.
266.507(d)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Add heading: Shipping non-creditable hazardous waste pharmaceuticals from a healthcare facility or evaluated hazardous waste pharmaceuticals from a reverse distributor.
266.508
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Shipping non-creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals. A healthcare facility must ship non-creditable hazardous waste pharmaceuticals and a reverse distributor must ship evaluated hazardous waste pharmaceuticals off-site to a designated facility (such as a permitted or interim status treatment, storage, or disposal facility) in compliance with:
266.508(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

The following pre-transport requirements, before transporting or offering for transport off-site:
266.508(a)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
                                       X

Packaging. Package the waste in accordance with the applicable Department of Transportation regulations on hazardous materials under 49 CFR parts 173, 178, and 180.
266.508(a)(1)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
Incorporated by reference in 9VAC20-110-110
                                       X

Labeling. Label each package in accordance with the applicable Department of Transportation regulations on hazardous materials under 49 CFR part 172 subpart E.
266.508(a)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
Incorporated by reference in 9VAC20-110-110
                                       X

Marking.
266.508(a)(1)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Mark each package of hazardous waste pharmaceuticals in accordance with the applicable Department of Transportation (DOT) regulations on hazardous materials under 49 CFR part 172 subpart D;
266.508(a)(1)(iii)(A)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
Incorporated by reference in 9VAC20-110-110
                                       X

Mark each container of 119 gallons or less used in such transportation with the following words and information in accordance with the requirements of 49 CFR 172.304:
HAZARDOUS WASTE -- Federal Law Prohibits Improper Disposal. If found, contact the nearest police or public safety authority or the U.S. Environmental Protection Agency.
Healthcare Facility's or Reverse distributor's Name and Address _____.
Healthcare Facility's or Reverse distributor's EPA Identification Number_____.
Manifest Tracking Number _____.
266.508(a)(1)(iii)(B)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
Incorporated by reference in 9VAC20-110-110
                                       X

Lab packs that will be incinerated in compliance with § 268.42(c) are not required to be marked with EPA Hazardous Waste Number(s), except D004, D005, D006, D007, D008, D010, and D011, where applicable. A nationally recognized electronic system, such as bar coding or radio frequency identification, may be used to identify the EPA Hazardous Waste Number(s).
266.508(a)(1)(iii)(C)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Placarding. Placard or offer the initial transporter the appropriate placards according to Department of Transportation regulations for hazardous materials under 49 CFR part 172 subpart F.
266.508(a)(1)(iv)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
Incorporated by reference in 9VAC20-110-110
                                       X

The manifest requirements of 40 CFR part 262 subpart B, except that:
266.508(a)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.
Incorporated by reference in 9VAC20-110-110
                                       X

A healthcare facility shipping non-creditable hazardous waste pharmaceuticals is not required to list all applicable hazardous waste numbers (i.e., hazardous waste codes) in Item 13 of EPA Form 8700-22.
266.508(a)(2)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A healthcare facility shipping non-creditable hazardous waste pharmaceuticals must write the word "PHARMS" in Item 13 of EPA Form 8700-22.
266.508(a)(2)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Exporting non-creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals. A healthcare facility or reverse distributor that exports non-creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals is subject to 40 CFR part 262 subpart H.
266.508(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Importing non-creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals. Any person that imports non-creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals is subject to 40 CFR part 262 subpart H. A healthcare facility or reverse distributor may not accept imported non-creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals unless they have a permit or interim status that allows them to accept hazardous waste from off site.
266.508(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Add heading: Shipping potentially creditable hazardous waste pharmaceuticals from a healthcare facility or a reverse distributor to a reverse distributor.
266.509
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Shipping potentially creditable hazardous waste pharmaceuticals. A healthcare facility or a reverse distributor who transports or offers for transport potentially creditable hazardous waste pharmaceuticals off-site to a reverse distributor must comply with all applicable U.S. Department of Transportation regulations in 49 CFR part 171 through 180 for any potentially creditable hazardous waste pharmaceutical that meets the definition of hazardous material in 49 CFR 171.8. For purposes of the Department of Transportation regulations, a material is considered a hazardous waste if it is subject to the Hazardous Waste Manifest Requirements of the U.S. Environmental Protection Agency specified in 40 CFR part 262. Because a potentially creditable hazardous waste pharmaceutical does not require a manifest, it is not considered hazardous waste under the Department of Transportation regulations.
266.509(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A. and B.4.

                                       X

Delivery confirmation. Upon receipt of each shipment of potentially creditable hazardous waste pharmaceuticals, the receiving reverse distributor must provide confirmation (paper or electronic) to the healthcare facility or reverse distributor that initiated the shipment that the shipment of potentially creditable hazardous waste pharmaceuticals has arrived at its destination and is under the custody and control of the reverse distributor.
266.509(b)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Procedures for when delivery confirmation is not received within 35 days. If a healthcare facility or reverse distributor initiates a shipment of potentially creditable hazardous waste pharmaceuticals to a reverse distributor and does not receive delivery confirmation within 35 calendar days from the date that the shipment of potentially creditable hazardous waste pharmaceuticals was sent, the healthcare facility or reverse distributor that initiated the shipment must contact the carrier and the intended recipient (i.e., the reverse distributor) promptly to report that the delivery confirmation was not received and to determine the status of the potentially creditable hazardous waste pharmaceuticals.
266.509(c)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Exporting potentially creditable hazardous waste pharmaceuticals. A healthcare facility or reverse distributor that sends potentially creditable hazardous waste pharmaceuticals to a foreign destination must comply with the applicable sections of 40 CFR part 262 subpart H, except the manifesting requirement of § 262.83(c), in addition to paragraphs (a) through (c) of this section.
266.509(d)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Importing potentially creditable hazardous waste pharmaceuticals. Any person that imports potentially creditable hazardous waste pharmaceuticals into the United States is subject to paragraphs (a) through (c) of this section in lieu of 40 CFR part 262 subpart H. Immediately after the potentially creditable hazardous waste pharmaceuticals enter the United States, they are subject to all applicable requirements of this subpart.
266.509(e)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Add heading: Standards for the management of potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals at reverse distributors.
266.510
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A reverse distributor may accept potentially creditable hazardous waste pharmaceuticals from off site and accumulate potentially creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals on site without a hazardous waste permit or without having interim status, provided that it complies with the following conditions:
266.510 Introductory paragraph
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Standards for reverse distributors managing potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals-
266.510(a)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Notification. A reverse distributor must notify the EPA Regional Administrator, using the Site Identification Form (EPA Form 8700-12), that it is a reverse distributor operating under this subpart.
266.510(a)(1)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A reverse distributor that already has an EPA identification number must notify the EPA Regional Administrator, using the Site Identification Form (EPA Form 8700-12), that it is a reverse distributor, as defined in § 266.500, within 60 days of the effective date of this subpart, or within 60 days of becoming subject to this subpart.
266.510(a)(1)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A reverse distributor that does not have an EPA identification number must obtain one by notifying the EPA Regional Administrator, using the Site Identification Form (EPA Form 8700-12), that it is a reverse distributor, as defined in § 266.500, within 60 days of the effective date of this subpart, or within 60 days of becoming subject to this subpart.
266.510(a)(1)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Inventory by the reverse distributor. A reverse distributor must maintain a current inventory of all the potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals that are accumulated on site.
266.510(a)(2)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A reverse distributor must inventory each potentially creditable hazardous waste pharmaceutical within 30 calendar days of each waste arriving at the reverse distributor.
266.510(a)(2)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

The inventory must include the identity (e.g., name or national drug code) and quantity of each potentially creditable hazardous waste pharmaceutical and evaluated hazardous waste pharmaceutical.
266.510(a)(2)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

If the reverse distributor already meets the inventory requirements of this paragraph because of other regulatory requirements, such as State Board of Pharmacy regulations, the facility is not required to provide a separate inventory pursuant to this section.
266.510(a)(2)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Evaluation by a reverse distributor that is not a manufacturer. A reverse distributor that is not a pharmaceutical manufacturer must evaluate a potentially creditable hazardous waste pharmaceutical within 30 calendar days of the waste arriving at the reverse distributor to establish whether it is destined for another reverse distributor for further evaluation or verification of manufacturer credit or for a permitted or interim status treatment, storage, or disposal facility.
266.510(a)(3)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A potentially creditable hazardous waste pharmaceutical that is destined for another reverse distributor is still considered a "potentially creditable hazardous waste pharmaceutical" and must be managed in accordance with paragraph (b) of this section.
266.510(a)(3)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A potentially creditable hazardous waste pharmaceutical that is destined for a permitted or interim status treatment, storage or disposal facility is considered an "evaluated hazardous waste pharmaceutical" and must be managed in accordance with paragraph (c) of this section.
266.510(a)(3)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Evaluation by a reverse distributor that is a manufacturer. A reverse distributor that is a pharmaceutical manufacturer must evaluate a potentially creditable hazardous waste pharmaceutical to verify manufacturer credit within 30 calendar days of the waste arriving at the facility and following the evaluation must manage the evaluated hazardous waste pharmaceuticals in accordance with paragraph (c) of this section.
266.510(a)(4)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Maximum accumulation time for hazardous waste pharmaceuticals at a reverse distributor.
266.510(a)(5)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A reverse distributor may accumulate potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals on site for 180 calendar days or less. The 180 days start after the potentially creditable hazardous waste pharmaceutical has been evaluated and applies to all hazardous waste pharmaceuticals accumulated on site, regardless of whether they are destined for another reverse distributor (i.e., potentially creditable hazardous waste pharmaceuticals) or a permitted or interim status treatment, storage, or disposal facility (i.e., evaluated hazardous waste pharmaceuticals).
266.510(a)(5)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Aging pharmaceuticals. Unexpired pharmaceuticals that are otherwise creditable but are awaiting their expiration date (i.e., aging in a holding morgue) can be accumulated for up to 180 days after the expiration date, provided that the unexpired pharmaceuticals are managed in accordance with paragraph (a) of this section and the container labeling and management standards in 266.510(c)(4)(i) through (vi).
266.510(a)(5)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Security at the reverse distributor facility. A reverse distributor must prevent unknowing entry and minimize the possibility for the unauthorized entry into the portion of the facility where potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals are kept.
266.510(a)(6)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Examples of methods that may be used to prevent unknowing entry and minimize the possibility for unauthorized entry include, but are not limited to:
266.510(a)(6)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A 24-hour continuous monitoring surveillance system;
266.510(a)(6)(i)(A)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

An artificial barrier such as a fence; or
266.510(a)(6)(i)(B)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A means to control entry, such as keycard access.
266.510(a)(6)(i)(C)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

If the reverse distributor already meets the security requirements of this paragraph because of other regulatory requirements, such as Drug Enforcement Administration or State Board of Pharmacy regulations, the facility is not required to provide separate security measures pursuant to this section.
266.510(a)(6)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Contingency plan and emergency procedures at a reverse distributor. A reverse distributor that accepts potentially creditable hazardous waste pharmaceuticals from off site must prepare a contingency plan and comply with the other requirements of 40 CFR part 262 subpart M.
266.510(a)(7)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Closure of a reverse distributor. When closing an area where a reverse distributor accumulates potentially creditable hazardous waste pharmaceuticals or evaluated hazardous waste pharmaceuticals, the reverse distributor must comply with § 262.17(a)(8)(ii) and (iii).
266.510(a)(8)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Reporting by a reverse distributor.
266.510(a)(9)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Unauthorized waste report. A reverse distributor must submit an unauthorized waste report if the reverse distributor receives waste from off site that it is not authorized to receive (e.g., non-pharmaceutical hazardous waste, regulated medical waste). The reverse distributor must prepare and submit an unauthorized waste report to the EPA Regional Administrator within 45 calendar days after the unauthorized waste arrives at the reverse distributor and must send a copy of the unauthorized waste report to the healthcare facility (or other entity) that sent the unauthorized waste. The reverse distributor must manage the unauthorized waste in accordance with all applicable regulations. The unauthorized waste report must be signed by the owner or operator of the reverse distributor, or its authorized representative, and contain the following information:
266.510(a)(9)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

The EPA identification number, name and address of the reverse distributor;
266.510(a)(9)(i)(A)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

The date the reverse distributor received the unauthorized waste;
266.510(a)(9)(i)(B)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

The EPA identification number, name, and address of the healthcare facility that shipped the unauthorized waste, if available;
266.510(a)(9)(i)(C)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A description and the quantity of each unauthorized waste the reverse distributor received;
266.510(a)(9)(i)(D)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

The method of treatment, storage, or disposal for each unauthorized waste; and
266.510(a)(9)(i)(E)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A brief explanation of why the waste was unauthorized, if known.
266.510(a)(9)(i)(F)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Additional reports. The EPA Regional Administrator may require reverse distributors to furnish additional reports concerning the quantities and disposition of potentially creditable hazardous waste pharmaceuticals and evaluated hazardous waste pharmaceuticals.
266.510(a)(9)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

Recordkeeping by reverse distributors. A reverse distributor must keep the following records (paper or electronic) readily available upon request by an inspector. The periods of retention referred to in this section are extended automatically during the course of any unresolved enforcement action regarding the regulated activity, or as requested by the EPA Regional Administrator.
266.510(a)(10)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A copy of its notification on file for as long as the facility is subject to this subpart;
266.510(a)(10)(i)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A copy of the delivery confirmation and the shipping papers for each shipment of potentially creditable hazardous waste pharmaceuticals that it receives, and a copy of each unauthorized waste report, for at least three years from the date the shipment arrives at the reverse distributor;
266.510(a)(10)(ii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X

A copy of its current inventory for as long as the facility is subject to this subpart.
266.510(a)(10)(iii)
9VAC20-60-18.
Incorporated by reference (IBR) in 9VAC20-60-266A.

                                       X


October 8, 2003 William C. Herz, MPH Director of Science Programs The Fertilizer Institute 820 First Street NE, Union Ctr Plaza Ste 430 Washington, DC 20002 ATTORNEY WORK PRODUCT  PRIVILEGED AND CONFIDENTIAL Dear Mr. Herz:

The chemical structure phosphoric acid, triammonium salt ( CAS# 10361 65 6) has been incorrectly depicted in the liquid polyphosphate dossier. The compound phosphoric acid, triammonium salt ( CAS# 10361 65 6) should be replaced with polyphosphoric acids, ammonium salts or ammonium polyphosphate ( CAS# 68333 79 9). The correct chemical formula and structure are as follows:

Please do not hesitate to contact me with any further questions or comments.

Very truly yours,

Michele A. Surricchio Consultant THE WEINBERG GROUP INC. MAS/ ms


[Federal Register Volume 77, Number 118 (Tuesday, June 19, 2012)]
[Notices]
[Pages 36524-36525]
[FR Doc No: 2012-14877]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 14421-000]

Freedom Falls, LLC; Notice of Application Tendered for Filing
With the Commission and Soliciting Additional Study Requests

    Take notice that the following hydroelectric application has been
filed with the Commission and is available for public inspection.
    a. Type of Application: Exemption from Licensing.
    b. Project No.: 14421-000.
    c. Date filed: June 1, 2012.
    d. Applicant: Freedom Falls, LLC.
    e. Name of Project: Freedom Falls Hydroelectric Project.
    f. Location: On Sandy Stream, in the Town of Freedom, Waldo County,

Maine. The project would not occupy lands of the United States.
    g. Filed Pursuant to: Public Utility Regulatory Policies Act of
1978, 16 U.S.C. 2705, 2708.
    h. Applicant Contact: Anthony P. Grassi, Freedom Falls LLC, 363
Belfast Road, Camden, ME 04843,<PHONE_NUMBER>.
    i. FERC Contact: Samantha Davidson,<PHONE_NUMBER> or
<EMAIL_ADDRESS>    j. Cooperating agencies: Federal, state, local, and tribal agencies
with jurisdiction and/or special expertise with respect to
environmental issues that wish to cooperate in the preparation of the
environmental document should follow the instructions for filing such
requests described in item l below. Cooperating agencies should note
the Commission's policy that agencies that cooperate in the preparation
of the environmental document cannot also intervene. See, 94 FERC ]
61,076 (2001).
    k. Pursuant to section 4.32(b)(7) of 18 CFR of the Commission's
regulations, if any resource agency, Indian Tribe, or person believes
that an additional scientific study should be conducted in order to
form an adequate factual basis for a complete analysis of the
application on its merit, the resource agency, Indian Tribe, or person
must file a request for a study with the Commission not later than 60
days from the date of filing of the application, and serve a copy of
the request on the applicant.
    l. Deadline for filing additional study requests and requests for
cooperating agency status: July 31, 2012.
    All documents may be filed electronically via the Internet. See 18
CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web
site http://www.ferc.gov/docs-filing/ferconline.asp. Commenters can
submit brief comments up to 6,000 characters, without prior
registration, using the eComment system at http://www.ferc.gov/docs-filing/ecomment.asp. You must include your name and contact information
at the end of your comments. For assistance, please contact FERC Online
Support at<EMAIL_ADDRESS>call toll-free at (866) 208-
3676; or, for TTY, contact<PHONE_NUMBER>. Although the Commission
strongly encourages electronic filing, documents may also be paper-
filed. To paper-file, mail an original and seven copies to: Kimberly D.
Bose, Secretary, Federal Energy Regulatory Commission, 888 First Street
NE., Washington, DC 20426.
    m. The application is not ready for environmental analysis at this
time.
    n. The proposed Freedom Falls Hydroelectric Project would consist
of: (1) An existing 90-foot-long, 12-foot-high concrete-capped stone
masonry dam with a 25-foot-long, 10-foot-high spillway with two
vertical lift sluice gates and a crest elevation of 452.5 feet mean sea
level (msl); (2) an existing 1.6-acre impoundment with a normal maximum
water surface elevation of 453.0 feet msl; (3) a new intake structure
equipped with an 8-foot-high, 5-foot-wide trashrack that would be
modified to have 1-inch clear bar spacing, and a 3-foot-high, 4.75-
foot-wide slide gate; (4) a new downstream American eel passage
facility and working platform; (5) a new 60-foot-long, 30-inch-diameter
steel penstock leading to; (6) an existing 20-foot-wide, by 30-foot-
long generating room containing a new 38.3 kilowatt turbine-generator
unit; (7) a new 20-foot-long, 5-foot-wide tailrace; (8) a new 30-foot-
long, 110-volt transmission line; and (9) appurtenant facilities. The
proposed project is estimated to generate an average of 66,000
kilowatt-hours annually.
    o. A copy of the application is available for review at the
Commission in the Public Reference Room or may be viewed on the
Commission's Web site at http://www.ferc.gov using the ``eLibrary''
link. Enter the docket number excluding the last three digits in the
docket number field to access the document. For assistance, contact
FERC Online Support.
    You may also register online at http://www.ferc.gov/docs-filing/esubscription.asp to be notified via email of new filings and issuances
related to this or other pending projects. For assistance, contact FERC
Online Support.
    p. With this notice, we are initiating consultation with the Maine
Historic Preservation Commission, as required by 106, National Historic
Preservation Act, and the regulations of the Advisory Council on
Historic Preservation, 36, CFR, at 800.4.
    q. Procedural schedule: The application will be processed according
to the following preliminary Hydro Licensing Schedule. Revisions to the
schedule will be made as appropriate (e.g., if scoping is waived, the
schedule would be shortened).

------------------------------------------------------------------------

------------------------------------------------------------------------
Issue Deficiency Letter................  August 2012.
Issue Notice of Acceptance.............  October 2012.
Issue Scoping Document.................  November 2012.
Issue Notice of ready for environmental  January 2013.
 analysis.
Issue Notice of the availability of the  May 2013.
 EA.
------------------------------------------------------------------------

    Dated: June 13, 2012.
Kimberly D. Bose,
 Secretary.
[FR Doc. 2012-14877 Filed 6-18-12; 8:45 am]
BILLING CODE 6717-01-P